Renal Support Network

We extend our sincere appreciation for the support of our corporate sponsors. Their generosity provides vital funding needed to fulfill our mission to make a lasting and positive difference in the lives of people who have kidney disease.

Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and services to more than 190,000 people with kidney disease at more than 2,400 facilities nationwide. Fresenius Kidney Care supports people by helping to address both the physical and emotional aspects of kidney disease through personalized care, education and lifestyle support services so they can lead meaningful and fulfilling lives.

U.S. Renal Care serves more than 23,000 patients in 300 dialysis facilities in 31 states and the Territory of Guam with a unique business model, developing and operating dialysis centers in joint venture partnerships with leading local nephrologists.

Akebia Therapeutics is a biopharmaceutical company with the purpose to better the life of each person impacted by kidney disease. We have both a commercially available product and a potential first-in-class product candidate for the treatment of anemia due to chronic kidney disease. We are located in the biotech hub of Cambridge, Massachusetts, where we are inspired by our peers and dedicated to working with our partners, patients, advocacy organizations and the broader kidney community.

CSL Vifor is a global partner of choice for innovative therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in global partnering, in-licensing and commercializing products with the aim to help patients around the world lead better, healthier lives.

Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.

Astrazenca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide.

DaVita is a leading provider of dialysis services to patients with chronic kidney failure and end stage renal disease.

Cara Therapeutics is advancing life-changing therapies for people suffering from chronic pruritus. Our proven science and expert team are changing the way pruritus is treated across a spectrum of diseases.

Since our Founder and Board Chairman Dr. Keith Johnson opened the first clinic in 1971 to care for eight patients in Nashville, Tenn., Dialysis Clinic, Inc. (DCI) has grown to be the nation’s largest not-for-profit dialysis provider with more than 240 locations across 28 states, serving nearly 14,000 patients each day. DCI’s mission states, “The care of the patient is our reason for existence.” DCI prioritizes a holistic approach and offers hemodialysis, home hemodialysis and peritoneal dialysis treatment options. DCI empowers patients to live meaningful and productive lives while also delivering high quality kidney care, saving lives and reducing hospitalizations. DCI is committed to advancing care through research and education to improve the lives of patients along the continuum of kidney health.

Transplant Genomics, Inc. (“TGI”) is a personalized diagnostics company committed to improving organ transplant outcomes worldwide through innovative tests that detect early signs of graft injury, differentiate among actionable causes, and enable the optimization of therapy. Working alongside the transplant community and within the Eurofins family, TGI is commercializing a suite of tests enabling diagnoses and prediction of transplant recipient immune status. TGI was acquired by Eurofins in 2019. Learn more about Transplant Genomics

At Horizon, we believe science and compassion must work together to transform lives. Our mission to deliver medicines for rare, autoimmune and severe inflammatory diseases and provide compassionate support comes from our strong and simple philosophy to make a meaningful difference for patients and communities in need.